| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Total revenue of $73 million in 2Q26, a 92% year-over-year increase – |
| 14 Jul 2026 |
8-K: Other Events
Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and simil... |
| 10 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE dated as of June 10, 2026 between SYNDAX PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking as... |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Adoption Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will become av... |
| 04 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
Syndax Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “Notes”). The Notes will be convertible into cash, shares (“Underlying Shares”) of common stock... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference |
| 19 Dec 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1 Registered Office. The registered office of Syndax Pharmaceuticals, Inc. (the “Corporation”) shall be at 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, Delaware 19808. |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
$45.9 million in total revenue, representing 21% growth over 2Q25 – |
| 24 Oct 2025 |
8-K: Other Events
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition
$28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – |
| 26 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 24, 2025, William Meury notified Syndax Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) due to his acceptance of the role of President and Chief Executive O... |
| 16 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 12th day of May, 2025 (the “Execution Date”), between NICHOLAS A.J. BOTWOOD BSC (HONS), MB BS, MFPM, FRCP (“Executive”) and Syndax Pharmaceuticals, Inc. (th... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition; Other Events
$20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – |
| 03 Mar 2025 |
8-K: Results of Operations and Financial Condition; Other Events
$7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – |
| 20 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 20, 2024, Syndax Pharmaceuticals, Inc. (the “Company”) announced that it has eliminated the Chief Medical Officer position and that Catherine Madigan, M.D. will cease to serve as the Company’s Chief Medical Officer and as an ... |
| 18 Nov 2024 |
8-K: Other Events
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation |
| 12 Nov 2024 |
8-K: Other Events
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib |
Loading...